Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Recent advances in CRISPR/Cas9 delivery approaches for therapeutic gene editing of stem cells
Rapid advancement in genome editing technologies has provided new promises for treating
neoplasia, cardiovascular, neurodegenerative, and monogenic disorders. Recently, the …
neoplasia, cardiovascular, neurodegenerative, and monogenic disorders. Recently, the …
CRISPR/Cas-based gene editing in therapeutic strategies for beta-thalassemia
S Zeng, S Lei, C Qu, Y Wang, S Teng, P Huang - Human Genetics, 2023 - Springer
Abstract Beta-thalassemia (β-thalassemia) is an autosomal recessive disorder caused by
point mutations, insertions, and deletions in the HBB gene cluster, resulting in the …
point mutations, insertions, and deletions in the HBB gene cluster, resulting in the …
Precision editing as a therapeutic approach for β-hemoglobinopathies
Beta-hemoglobinopathies are the most common genetic disorders worldwide, caused by a
wide spectrum of mutations in the β-globin locus, and associated with morbidity and early …
wide spectrum of mutations in the β-globin locus, and associated with morbidity and early …
[HTML][HTML] Efficient CRISPR-Cas9-based genome editing of β-globin gene on erythroid cells from homozygous β039-thalassemia patients
Gene editing by the CRISPR-Cas9 nuclease system technology can be considered among
the most promising strategies to correct hereditary mutations in a variety of monogenic …
the most promising strategies to correct hereditary mutations in a variety of monogenic …
Combined approaches for increasing fetal hemoglobin (HbF) and de novo production of adult hemoglobin (HbA) in erythroid cells from β-thalassemia patients …
Genome editing (GE) is one of the most efficient and useful molecular approaches to correct
the effects of gene mutations in hereditary monogenetic diseases, including β-thalassemia …
the effects of gene mutations in hereditary monogenetic diseases, including β-thalassemia …
[HTML][HTML] Epigenetic Insights and Potential Modifiers as Therapeutic Targets in β–Thalassemia
Thalassemia, an inherited quantitative globin disorder, consists of two types, α–and β–
thalassemia. β–thalassemia is a heterogeneous disease that can be asymptomatic, mild, or …
thalassemia. β–thalassemia is a heterogeneous disease that can be asymptomatic, mild, or …
CRISPR/Cas9, a promising approach for the treatment of β-thalassemia: A systematic review
The CRISPR/Cas9 technique is easily programmable, fast, more powerful, and efficient at
generating a mutation compared to previous gene therapy methods. β-thalassemia is the …
generating a mutation compared to previous gene therapy methods. β-thalassemia is the …
[HTML][HTML] CRISPR technology: A versatile tool to model, screen, and reverse drug resistance in cancer
Background Drug resistance is a serious challenge in cancer treatment that can render
chemotherapy a failure. Understanding the mechanisms behind drug resistance and …
chemotherapy a failure. Understanding the mechanisms behind drug resistance and …
Genome editing approaches to β-hemoglobinopathies
Abstract β-hemoglobinopathies are the most common monogenic disorders worldwide and
are caused by mutations in the β-globin locus altering the production of adult hemoglobin …
are caused by mutations in the β-globin locus altering the production of adult hemoglobin …
CRISPR-Cas9 to induce fetal hemoglobin for the treatment of sickle cell disease
Genome editing is potentially a curative technique available to all individuals with β-
hemoglobinopathies, including sickle cell disease (SCD). Fetal hemoglobin (HbF) inhibits …
hemoglobinopathies, including sickle cell disease (SCD). Fetal hemoglobin (HbF) inhibits …